MX2023012447A - Ergolinas novedosas y metodos para tratar los desordenes del humor. - Google Patents

Ergolinas novedosas y metodos para tratar los desordenes del humor.

Info

Publication number
MX2023012447A
MX2023012447A MX2023012447A MX2023012447A MX2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A
Authority
MX
Mexico
Prior art keywords
methods
mood disorders
ergolines
novel
treating mood
Prior art date
Application number
MX2023012447A
Other languages
English (en)
Inventor
Andrew Carry Kruegel
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Publication of MX2023012447A publication Critical patent/MX2023012447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción proporciona compuestos de ergolina y su uso para tratar los trastornos del humor. Se proporcionan las composiciones y métodos farmacéuticos para hacer los varios compuestos de ergolina.
MX2023012447A 2021-04-23 2022-04-25 Ergolinas novedosas y metodos para tratar los desordenes del humor. MX2023012447A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179053P 2021-04-23 2021-04-23
US202263308376P 2022-02-09 2022-02-09
PCT/US2022/026186 WO2022226408A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Publications (1)

Publication Number Publication Date
MX2023012447A true MX2023012447A (es) 2023-10-31

Family

ID=81648213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012447A MX2023012447A (es) 2021-04-23 2022-04-25 Ergolinas novedosas y metodos para tratar los desordenes del humor.

Country Status (9)

Country Link
EP (1) EP4326718A1 (es)
JP (1) JP2024516174A (es)
KR (1) KR20240019091A (es)
AU (1) AU2022262659A1 (es)
BR (1) BR112023021970A2 (es)
CA (1) CA3223210A1 (es)
IL (1) IL307880A (es)
MX (1) MX2023012447A (es)
WO (1) WO2022226408A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230414583A1 (en) * 2022-06-20 2023-12-28 Mind Medicine, Inc. Lysergic acid derivatives with modified lsd-like action

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US20230286975A1 (en) * 2020-07-07 2023-09-14 Compass Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof

Also Published As

Publication number Publication date
JP2024516174A (ja) 2024-04-12
BR112023021970A2 (pt) 2023-12-26
WO2022226408A1 (en) 2022-10-27
AU2022262659A1 (en) 2023-10-19
IL307880A (en) 2023-12-01
CA3223210A1 (en) 2022-12-27
KR20240019091A (ko) 2024-02-14
EP4326718A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
EP4295846A3 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021009037A (es) Composiciones y metodos para el manejo de trastornos.
CR20220170A (es) Aminas bicíclicas como inhibidoras de la cdk2
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
MX2022010797A (es) Composiciones novedosas y metodos.
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MY192255A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2022006807A (es) Análogos de rapamicina y usos de estos.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
MX2019004070A (es) Sistema de extraccion de un sistema de circuito cerrado.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
MX2023012447A (es) Ergolinas novedosas y metodos para tratar los desordenes del humor.
WO2024091506A3 (en) Novel ergolines and methods of treating mood disorders
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2021004517A (es) Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
EP4171606A4 (en) COMPOSITIONS AND METHODS FOR TREATING COVID-19
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.